BIOASTER, today announced a collaboration with QIAGEN for the development of a molecular diagnostic assay running on the QIAGEN’s QIAstat-Dx platform. The primary objective of the collaboration is to expand...
We are pleased to share with you the press release on our joint “S.O.L.V.E. AMR” initiative with Cynbiose, Pharmalex and ICTA. S.O.L.V.E AMR (Solutions for Overcoming and Leveraging Versatile Efforts...
Onchocerciasis, also known as river blindness, stands as the second leading cause of infectious blindness worldwide. According to estimates by the World Health Organization (WHO), approximately 25 million...
PiLeJe Laboratoire and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights on the immunomodulatory potential of selected probiotics in the context of...
Kaleido Biosciences and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights into ways Kaleido’s Microbiome Metabolic Therapies (MMT™) modulate the integrity and function of...
PiLeJe Laboratoire to collaborate with BIOASTER to investigate the health potential of a probiotic selection Pileje Laboratoire, a French company leader in probiotic-based dietary supplements in Europe and specialized in...
@BIOASTER receives $885K grant from the Bill & Melinda Gates Foundation @gatesfoundation to develop #Onchocerciasis advanced rapid #diagnostic with @mologic Ltd. BIOASTER, today announced it has received a grant in...
Kaleido Biosciences to collaborate with BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome. Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and...
BIOASTER announces a collaboration with Exeliom Biosciences, a leading biotech in the developement of innovative microbiome-based therapies, located in Paris and Dijon, France. The aim of the partnership is to...
BIOASTER announces the kick off a new IMI project “GNA NOW” (Gram-Negative Antibacterials NOW), led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI),...
BIOASTER announced the signature of a collaboration agreement with Pherecydes Pharma, a French Biotechnology company, with the objective of discovering lytic bacteriophages, to be developed into a pharmaceutical solution to...
BIOASTER teams are currently in Utrecht for the kick-off meeting of the European project GNA-NOW, part of the AMR Accelerator Programme of IMI 2. We are proud to be part...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
